Trial Profile

A phase 3 pivotal study evaluating SM-020 for the treatment of seborrheic keratosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SM-020 (Primary)
Indications Seborrhoeic keratosis
Focus Registrational; Therapeutic Use
Sponsors DermBiont

Most Recent Events

22 Feb 2024 According to a DermBiont media release, positive results from Phase 2b clinical trial will support End of Phase 2 Meeting with FDA submission package to the FDA in Q4 2024 and ultimate regulatory alignment for designing DermBionts Phase 3 pivotal trial.
30 Jun 2022 New trial record
23 Jun 2022 According to a DermBiont media release, this trial plans to initiate as early as Q1 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com